Low Dose THC
Phase 2Small molecule
Low Dose THC is one of 166 small molecule programs targeting Down syndrome. It is currently in Phase 2.
6
Indications
14
Total Trials
6
Active Trials
165
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Daliresp
AstraZenecaPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Lisdexamfetamine Dimesylate
TakedaPhase 3
Bupropion XL
GSKPhase 3
Desvenlafaxine SR
PfizerPhase 3
SPD489
TakedaPhase 3
Venlafaxine ER
PfizerPhase 3
Antidepressant Therapy
AbbViePhase 3
Saredutant
SanofiPhase 3
Amibegron (SR58611A)
SanofiPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Impairment2 trials
Major Depressive Disorder1 trial
8 more indications
Imaging1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Low Dose THC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- YYale University